[Edaily Reporter YU JIN-HEE ] As the domestic securities market has recently entered a period of consolidation for semiconductor and key information technology (IT) stocks, investor sentiment is rapidly shifting back toward the pharmaceutical and biotech sectors. In particular, a clear preference for “medium-risk, high-return” investments is emerging, centered on small- and mid-cap stocks that have demonstrated momentum through factors such as top management’s strong commitment to boosting stock prices, differentiated core technologies, and proven financial turnarounds.

KMPHARMACEUTICAL Co.,Ltd.: Major Shareholder Contributes 1 Billion Won from Personal Funds; Company Makes All-Out Effort to Resolve Extreme Undervaluation at a PBR of 0.2x

According to KG Zeroin MP Doctor (MP DOCTOR), on the 30th, KMPHARMACEUTICAL Co.,Ltd.(225430), #LEMON COMPANY LIMITED, and JW SHINYAK CORPORATION(067290) were among the “Top 15” gainers on the domestic stock market, demonstrating the resilience of three pharmaceutical and biotech stocks. KMPHARMACEUTICAL Co.,Ltd. surged 30.00% (closing price: 1,755 won) from the previous trading day, soaring to the daily price limit, while LEMON COMPANY LIMITED also jumped 29.85% (5,350 won) to hit the upper price limit. JW SHINYAK CORPORATION also closed with a strong upward trend, rising significantly by 15.57% (1,811 won).

The primary driving force behind KMPHARMACEUTICAL Co.,Ltd.’s strong stock performance—which was the first to reach the upper price limit—stemmed from the top management’s commitment to responsible leadership and comprehensive shareholder-friendly policies. To overcome the adverse situation of being designated a KOSDAQ “monitored stock” due to insufficient market capitalization and restore the company’s value, KMPHARMACEUTICAL Co.,Ltd. took a decisive stand by having both management and the company simultaneously inject funds.

Baek Seung-won, CEO of KMPHARMACEUTICAL Co.,Ltd., personally contributed approximately 1 billion won of his own funds to participate in a third-party private placement, and the company completed the payment without a hitch on the 24th. Furthermore, the company demonstrated its strong commitment to stabilizing the stock price by deciding to repurchase 300 million won worth of its own shares, equivalent to 3.72% of the issued shares. Chairman Kang Il-mo, the largest shareholder, has also been continuously buying shares on the open market, raising the combined stake held by the largest shareholder and related parties to 39.6%. Furthermore, the company has implemented a range of self-rescue measures, including exploring the sale of its Seoul sales office to secure funds for improving its financial structure.

From a technology and asset perspective, the company’s extreme undervaluation—with a price-to-book ratio (PBR) of just 0.27—was re-evaluated by the market. Based on its manufacturing technology for over-the-counter products and cosmetics, KMPHARMACEUTICAL Co.,Ltd. possesses state-of-the-art Good Manufacturing Practice (GMP) production infrastructure and real estate assets that enable it to independently produce its flagship product, “Pororo Toothpaste,” as well as infant oral care products and a lineup of lotions and bath products made from natural ingredients designed to minimize skin irritation. Analysts attribute the surge in value-investing demand to the company’s robust shareholder return policy, announced amid assessments that its market capitalization was excessively low relative to the value of its assets.

Leveraging the strength of its flagship brands, KMPHARMACEUTICAL Co.,Ltd. is densely reorganizing its distribution networks in key existing Asian markets such as China and Vietnam, while simultaneously pushing forward in earnest to enter the North American market based on the competitiveness of its own brands. Alongside this, the company’s strategy is to actively expand its order volume for private-label (OEM) and original design manufacturing (ODM) contracts to restore profitability in its core business.

For KMPHARMACEUTICAL Co.,Ltd. to move beyond a short-term stock price surge and settle into a long-term upward trajectory, it must not only meet the requirement to “maintain a market capitalization of 20 billion won”—a condition for removal from the watch list—but also achieve a definitive return to profitability in its core business. Last year, KMPHARMACEUTICAL Co.,Ltd. recorded consolidated revenue of 15.99 billion won, marking a 10.5% year-over-year increase in revenue; however, it posted an operating loss of 2.92 billion won, indicating a widening deficit.

In a recent Seohan to shareholders, CEO Baek emphasized, “We are making the removal of the ‘under observation’ designation and the restoration of corporate value our top management priorities,” adding, “We will do our utmost to regain market trust and maximize corporate value through responsible management and consistent shareholder-friendly policies.”

Lemon Healthcare: A Pipeline of 120 Million Medical Data Records and the Technological Moat of the LDB Platform

Lemon Healthcare, a mobile healthcare data platform company, reached its daily price limit as the value of its core technology, “Lemon Data Bridge” (LDB)—which has been certified with an A·A rating in a technology evaluation—converged with the momentum of its IPO push.

Lemon Healthcare’s core competitive advantage lies in LDB, a proprietary platform architecture that organically integrates the closed electronic medical record (EMR) and picture archiving and communication systems (PACS) of large hospitals. Lemon Healthcare defines itself not as a mere system integration (SI) company, but as a technology firm specializing in real-time, bidirectional medical data relay platforms. The LDB technology consists of three core modules. These include “LEMON COMPANY LIMITED PrivateAPI,” which standardizes APIs by service purpose; “QAB” (QueryAgentBox), a standard integration module that enables secure, real-time data relay even within a hospital’s closed network environment; and “F-Flow,” an integrated operational framework that monitors and manages the entire data flow.

This platform is implemented through three solution lineups: Hospital Smart Services (LDB-H), Electronic Documents and Certification (LDB-E), and Data Relay (LDB-D). Designed based on a common architecture, it features a Software-as-a-Service (SaaS) structure that allows new hospitals to be integrated immediately—simply by expanding accounts—without the need for a separate, complex development process. Nearly a decade of real-time integration and operational experience, gained through deployments at over 130 leading tertiary and large-scale hospitals in Korea—including Seoul National University Hospital and Severance Hospital—has created a formidable technological barrier to entry that cannot be quickly overcome by financial resources alone. Approximately 30 domestic and 10 international patents further reinforce this technological moat.

In addition, LEMON COMPANY LIMITED has accumulated over 120 million records of high-quality medical data obtained with patient consent through its flagship app, “Claim God.” By establishing a pipeline system to reliably supply this standardized, large-scale data to AI, pharmaceutical, and healthcare IT companies, the company has completed its transformation from a simple medical solutions provider into a medical AI data platform company.

Financially, the company is also presenting a roadmap for a turnaround. Unlike many biotech and healthcare companies pursuing a listing under the technology exception that are plagued by chronic losses, LEMON COMPANY LIMITED has demonstrated a structure capable of generating actual profits. Last year, the company recorded revenue of 15.9 billion won and an operating loss of 600 million won, significantly reducing its deficit. For this year, the company has officially forecast its first-ever operating profit since its founding, with revenue of 24.1 billion won and an operating profit of 6.5 billion won.

Lemon Healthcare’s mid- to long-term enterprise value depends on whether it achieves this year’s target of a 6.5 billion won operating profit, as well as on expanding the share of revenue from the commercialization of medical AI data. The recent acceleration in the expansion of its simplified medical expense insurance claims system (“Silseon24”) and the development of a personalized medical MyData ecosystem is expected to provide Lemon Healthcare with a vast Chonbang market.

A Lemon Healthcare official emphasized, “The experience in platform integration and data operations accumulated over the past 10 years through collaboration with 130 major hospitals in Korea acts as a barrier to entry that cannot be easily overcome even with financial resources,” adding, “This solid foundation of experience will serve as the cornerstone for securing an overwhelming advantage in future competition with large corporations.”

JW SHINYAK CORPORATION Organically Integrates ‘Ducray’ to Strengthen Its Prescription Drug and Dermacosmetic Portfolios

JW SHINYAK CORPORATION, a KOSDAQ-listed pharmaceutical company affiliated with the JW Group, has successfully expanded its reach into the rapidly growing dermocosmetics (functional cosmetics) market for hair loss management, building on its existing, unrivaled prescription drug sales network for clinics, and has thereby generated new growth momentum.

JW SHINYAK CORPORATION is a manufacturer and distributor of prescription drugs that boasts a solid sales network and product competitiveness in the clinic-level market, including dermatology, urology, pediatrics, and otolaryngology. The company has established a stable foundation for its performance based on a lineup of original and generic prescription drugs, including the antifungal agents “Hitrazole” and “Oneflu Capsules,” and the dermatological treatment “PD Tablets.” In particular, in the hair loss treatment sector, the company maintains a strong portfolio that includes “Monad” and “Monasta” (containing finasteride), “Dutamoa” (containing dutasteride), and the topical minoxidil solution “Mydil 5% Foam.” Among these, ‘Monad,’ the company’s flagship product, has consistently generated annual sales of around 3 billion won as a single product, serving as the company’s main revenue driver.

What sets JW SHINYAK CORPORATION’s core technology and business strategy apart is its ability to anticipate shifts in the hair loss market paradigm and establish an integrated solution that combines “treatment (pharmaceuticals)” with “daily care (dermocosmetics).” JW SHINYAK CORPORATION signed an exclusive supply agreement with Pierre Fabre, a leading French pharmaceutical company, and exclusively introduced the global hair care brand “Ducray Neo-Peptide Expert” to the Korean market.

JW SHINYAK CORPORATION is prioritizing the supply of this product to its long-established sales network of dermatology and hair loss clinics, while simultaneously expanding its consumer reach through a two-track strategy that leverages both its official online store and online and offline beauty channels. With hair loss-related products currently accounting for approximately 10% of total sales, the addition of this high-margin dermocosmetic lineup is emerging as a key driver in elevating the company’s overall profitability.

A JW SHINYAK CORPORATION official stated, “The product excellence of the Ducray brand, already proven in the global market, is creating synergy when combined with JW SHINYAK CORPORATION’s robust sales infrastructure in dermatology clinics,” adding, “We will cultivate an integrated hair loss portfolio—combining therapeutic treatments and functional cosmetics—as a core growth driver for the company’s future.”